Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has a beta value of 0.77 and has seen 1.12 million shares traded in the recent trading session. The company, currently valued at $1.94B, closed the recent trade at $8.98 per share which meant it gained $0.11 on the day or 1.18% during that session. The RXRX stock price is -86.53% off its 52-week high price of $16.75 and 49.44% above the 52-week low of $4.54. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.97 million shares traded. The 3-month trading volume is 7.06 million shares.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Sporting 1.18% in the green today, the stock has traded in the red over the last five days, when the RXRX stock price touched $8.98 or saw a rise of 3.96%. Year-to-date, Recursion Pharmaceuticals Inc shares have moved -8.98%, while the 5-day performance has seen it change -4.22%. Over the past 30 days, the shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have changed -19.51%. Short interest in the company has seen 43.52 million shares shorted with days to cover at 4.45.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Figures show that Recursion Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 26.23% over the past 6 months, with this year growth rate of -3.16%, compared to 9.20% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -23.50% and -10.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 26.00%.
6 analysts offering their estimates for the company have set an average revenue estimate of $12.65 million for the current quarter. 6 have an estimated revenue figure of $13.17 million for the next quarter concluding in Jun 2024. Year-ago sales stood $12.13 million and $11.02 million respectively for this quarter and the next, and analysts expect sales will grow by 4.30% for the current quarter and 19.50% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -43.41% over the past 5 years. Earnings growth for 2024 is a modest -9.14% while over the next 5 years, the company’s earnings are expected to increase by 12.00%.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next earnings report between May 06 and May 10 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Insiders own 5.77% of the company shares, while shares held by institutions stand at 92.41% with a share float percentage of 98.06%. Investors are also buoyed by the number of investors in a company, with Recursion Pharmaceuticals Inc having a total of 283 institutions that hold shares in the company. The top two institutional holders are Baillie Gifford and Company with over 25.1 million shares worth more than $187.48 million. As of Jun 29, 2023, Baillie Gifford and Company held 12.30% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 11.62 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $86.8 million and represent 5.69% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and Vanguard U.S. Growth Fund. As of Sep 29, 2023, the former fund manager holds about 3.33% shares in the company for having 6.8 million shares of worth $52.0 million while later fund manager owns 3.97 million shares of worth $34.85 million as of May 30, 2023, which makes it owner of about 1.95% of company’s outstanding stock.
